Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Severe Losses ALMS has ample liquidity and low debt, but extreme losses, rapid cash burn, and a premium valuation make the shares high risk pending clear operational improvement.
Price Behavior
Key Price Behavior Insights: ⢠Sharp Downtrend ⢠Key Support ⢠Failed Rebounds Support Level: $7.77 Resistance Level: $8.40â$9.22 ALMS remains technically weak after a ~66% last-month decline, with $7.77 support critical and recovery requiring a break above $9.22.
Sentiment & News
Key News Insights: ⢠Lupus trial miss ⢠Subgroup signal ⢠Psoriasis on track Alumis' lupus trial failure is a major setback, but promising subgroup data and its on-track psoriasis filing preserve upside potential.
AI Summary
ALMS is now a high-risk, psoriasis-led regulatory investment: the Q4 2026 envudeucitinib NDA is the pivotal value catalyst, while the failed broad SLE study reduces lupus to a speculative biomarker option. Investors should await evidence of filing/approval progress and protect against downside from heavy cash burn, potential dilution, and failure to reclaim clinical or commercial differentiation in a crowded psoriasis market.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |